239.14 USD
-5.41 (-2.21%)
239.14 USD
0 (0%)
NTRA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTRA as it has an excellent financial health rating, but there are worries on the profitability. NTRA is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year NTRA has reported negative net income.
NTRA had a positive operating cash flow in the past year.
NTRA had negative earnings in each of the past 5 years.
NTRA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -16.97%, NTRA is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
With a decent Return On Equity value of -24.69%, NTRA is doing good in the industry, outperforming 79.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.97% | ||
| ROE | -24.69% | ||
| ROIC | N/A |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NTRA (63.66%) is better than 79.28% of its industry peers.
NTRA's Gross Margin has improved in the last couple of years.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NTRA has been increased compared to 5 years ago.
NTRA has a better debt/assets ratio than last year.
2.2 Solvency
NTRA has an Altman-Z score of 34.59. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 34.59, NTRA belongs to the best of the industry, outperforming 94.35% of the companies in the same industry.
NTRA has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.86, NTRA belongs to the top of the industry, outperforming 93.97% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
NTRA's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. NTRA is outperformed by 61.96% of its industry peers.
Even though the debt/equity ratio score it not favorable for NTRA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.86 | ||
| Altman-Z | 34.59 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
A Current Ratio of 3.27 indicates that NTRA has no problem at all paying its short term obligations.
NTRA has a worse Current ratio (3.27) than 62.34% of its industry peers.
A Quick Ratio of 3.13 indicates that NTRA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.13, NTRA is doing worse than 61.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.27 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
NTRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.11%.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 38.17%.
NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.20% yearly.
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
3.2 Future
NTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.73% yearly.
Based on estimates for the next years, NTRA will show a very strong growth in Revenue. The Revenue will grow by 20.32% on average per year.
EPS Next Y-57.33%
EPS Next 2Y-9.16%
EPS Next 3Y21.76%
EPS Next 5Y30.73%
Revenue Next Year33.31%
Revenue Next 2Y24.63%
Revenue Next 3Y22.75%
Revenue Next 5Y20.32%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, NTRA is valued cheaply inside the industry as 89.83% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 352.74 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRA's earnings are expected to grow with 21.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.16%
EPS Next 3Y21.76%
5. Dividend
5.1 Amount
NTRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
239.14
-5.41 (-2.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.21%
Inst Owner Change10.03%
Ins Owners3.03%
Ins Owner Change-2.3%
Market Cap33.00B
Revenue(TTM)2.12B
Net Income(TTM)-309.19M
Analysts84.44
Price Target237.23 (-0.8%)
Short Float %2.82%
Short Ratio2.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.99%
Min EPS beat(2)-68.19%
Max EPS beat(2)-17.78%
EPS beat(4)1
Avg EPS beat(4)-16.42%
Min EPS beat(4)-68.19%
Max EPS beat(4)23.06%
EPS beat(8)5
Avg EPS beat(8)10.4%
EPS beat(12)8
Avg EPS beat(12)8.32%
EPS beat(16)11
Avg EPS beat(16)6.86%
Revenue beat(2)2
Avg Revenue beat(2)12.87%
Min Revenue beat(2)12.51%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.23%
Min Revenue beat(4)8.92%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)12.89%
Revenue beat(12)11
Avg Revenue beat(12)9.45%
Revenue beat(16)14
Avg Revenue beat(16)7.54%
PT rev (1m)19.39%
PT rev (3m)17.53%
EPS NQ rev (1m)-24.58%
EPS NQ rev (3m)-30.21%
EPS NY rev (1m)-18.49%
EPS NY rev (3m)-22.82%
Revenue NQ rev (1m)3.97%
Revenue NQ rev (3m)7.17%
Revenue NY rev (1m)5.63%
Revenue NY rev (3m)7.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 15.59 | ||
| P/FCF | 352.74 | ||
| P/OCF | 169.86 | ||
| P/B | 26.36 | ||
| P/tB | 26.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.29
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)0.68
FCFY0.28%
OCF(TTM)1.41
OCFY0.59%
SpS15.34
BVpS9.07
TBVpS9.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.97% | ||
| ROE | -24.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.66% | ||
| FCFM | 4.42% |
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score5
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.86 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 270.95% | ||
| Cap/Sales | 4.76% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.27 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 34.59 |
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.15%
EPS Next Y-57.33%
EPS Next 2Y-9.16%
EPS Next 3Y21.76%
EPS Next 5Y30.73%
Revenue 1Y (TTM)38.17%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%34.66%
Revenue Next Year33.31%
Revenue Next 2Y24.63%
Revenue Next 3Y22.75%
Revenue Next 5Y20.32%
EBIT growth 1Y-45.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-58.34%
EBIT Next 3Y31.8%
EBIT Next 5Y35.26%
FCF growth 1Y130.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y171.97%
OCF growth 3YN/A
OCF growth 5YN/A
NATERA INC / NTRA FAQ
What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NTRA.
Can you provide the valuation status for NATERA INC?
ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.
How profitable is NATERA INC (NTRA) stock?
NATERA INC (NTRA) has a profitability rating of 2 / 10.